Lessons from hypertension trials

American Journal of Medicine

Volumn 104, Issue 6 A, 1998, Pages 50S-53S

  Hennekens, Charles H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; BEHAVIOR MODIFICATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; HEART INFARCTION; HUMAN; HYPERTENSION; LIFESTYLE; MORTALITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SODIUM RESTRICTION; STROKE;

EID: 0031830717     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(98)00188-0     Document Type: Review

References (30)

1. Hennekens CH. The increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation. 1998;97:1095-1102.
2. Dawber TR. The Framingham Study: The Epidemiology of Atherosclerotic Disease. Cambridge: Harvard University Press, 1980.
3. Hypertension Detection and Follow-up Program Cooperative Group. The Hypertension Detection and Follow-up Program: a progress report. Circ Res. 1977;40(suppl l):l-106-I-109.
4. World Health Organization/International Society of Hypertension, Mild Hypertension Liaison Committee. Trials of the treatment of mild hypertension: an interim analysis. Lancet. 1982;i:149-156.
5. Toth PJ, Horwitz RI. Conflicting clinical trials and the uncertainty of treating mild hypertension. Am J Med. 1983;75: 482-488.
6. Sacks HS, Chalmers TC, Berk AA, Reitman D. Should mild hypertension be treated? An attempted meta-analysis of the clinical trials. Mt Sinai J Med. 1985;52:265-270.
7. Cutler JA, Furberg CD. Drug treatment in hypertension: a review. Prev Med. 1985;14:499-518.
8. Labarthe DR. Mild hypertension: the question of treatment. Ann Rev Public Health. 1986;7:193-215.
9. Hebert PR, Fiebach NH, Eberlein KA, Taylor JO, Hennekens CH. The community-based randomized trials of pharmacologic treatment of mild-to-moderate hypertension. Am J Epidemiol. 1988;127:581-590.
10. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335: 827-838.
11. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990; 335:765-774.
12. Miall WE, Greenberg G. Mild hypertension: is there pressure to treat? An account of the MRC trial. Cambridge: Cambridge University Press; 1987:78-152.
13. Holland OB, Nixon JV, Kuhnert L Diuretic-induced ventricular ectopic activity. Am J Med. 1981;70:762-768.
14. Papademetriou V, Flether R, Khatri IM, Freis ED. Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias. Am J Cardiol. 1983;52:1017-1022.
15. Ames RP, Hill P. Elevation of serum lipid levels during diuretic therapy of hypertension. Am J Med. 1976;61:748-757.
16. Grimm RH Jr, Leon AS, Hunninghake DB, et al. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial. Ann Intern Med. 1981;94:7-11.
17. Johnson BF. The emerging problem of plasma lipid changes during antihypertensive therapy. J Cardiovasc Pharmacol. 1982;4(suppl 2):S213-S221.
18. Weidmann P, Gerber A, Mordasini R. Effects of antihypertensive therapy on serum lipoproteins. Hypertension. 1983; 5(suppl III):III-120-III-131.
19. Weidmann P, Uehlinger DE, Gerber A. Antihypertensive treatment and serum lipoproteins. J Hypertens. 1985;3: 297-306.
20. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989; 321:868-873.
21. Curb JD, Maxwell MH, Schneider KA, Taylor JO, Shulman NB. Adverse effects of antihypertensive medications in the Hypertension Detection and Follow-up Program. Prog Cardiovasc Dis. 1986;29(suppl 1):73-88.
22. Peto R, Yusuf S, Collins R. Cholesterol-lowering trial results in their epidemiologic context. (Abstr.) Circulation. 1985; 72(suppl III):451.
23. Wilhelmsen L, Berglund G, Elmfeldt D, et al. The multi-factor primary prevention trial in Göteborg, Sweden. Eur Heart J. 1986;7:279-288.
24. Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 1993;153:578-581.
25. Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
26. Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997; 157:2413-2445.
27. Siegel D, Lopez J. Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? JAMA. 1997;278:1745-1748.
28. Lenfant C. JNC guidelines: is the message getting through? JAMA. 1997;278:1778-1779.
29. Davis BR, Cutler JA, Gordon DJ, et al, for the ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342-360.
30. Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med. 1995;155:701-709.